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Mingkui Zhou1 and Ruth M Ruprecht1,2*Abstract
An estimated 90% of all HIV transmissions occur mucosally. Immunoglobulin A (IgA) molecules are important
components of mucosal fluids. In a vaccine efficacy study, in which virosomes displaying HIV gp41 antigens
protected most rhesus monkeys (RMs) against simian-human immunodeficiency virus (SHIV), protection correlated
with vaginal IgA capable of blocking HIV transcytosis in vitro. Furthermore, vaginal IgG exhibiting virus neutralization
and/or antibody-dependent cellular cytotoxicity (ADCC) correlated with prevention of systemic infection. In contrast,
plasma IgG had neither neutralizing nor ADCC activity. More recently, a passive mucosal immunization study provided
the first direct proof that dimeric IgAs (dIgAs) can prevent SHIV acquisition in RMs challenged mucosally. This
study compared dimeric IgA1 (dIgA1), dIgA2, or IgG1 versions of a human neutralizing monoclonal antibody
(nmAb) targeting a conserved HIV Env epitope. While the nmAb neutralization profiles were identical in vitro, dIgA1
was significantly more protective in vivo than dIgA2. Protection was linked to a new mechanism: virion capture.
Protection also correlated with inhibition of transcytosis of cell-free virus in vitro. While both of these primate model
studies demonstrated protective effects of mucosal IgAs, the RV144 clinical trial identified plasma IgA responses to HIV
Env as risk factors for increased HIV acquisition. In a secondary analysis of RV144, plasma IgA decreased the in vitro
ADCC activity of vaccine-induced, Env-specific IgG with the same epitope specificity. Here we review the current
literature regarding the potential of IgA – systemic as well as mucosal – in modulating virus acquisition and address
the question whether anti-HIV IgA responses could help or harm the host.
Keywords: IgA, Dimeric IgA1 (dIgA1), dIgA2, Secretory IgA (SIgA), HIV/SHIV, Mucosal transmission, Passive
immunization, Non-human primate models, RV144 trial, AIDS vaccine developmentIntroduction
Mucosal secretions represent the first line of defense to
protect a host against invasion of viral pathogens, including
HIV. Dimeric or polymeric IgA molecules are important
components of mucosal fluids; IgA is present in vaginal and
rectal secretions, in saliva, gastric fluid, tears, sweat and in
colostrum as well as mature milk. Monomeric IgA is
also one of the major immunoglobulin classes present
in serum, second only to IgG. In humans, the production
of IgA per day is greater than that of the other classes of
immunoglobulins combined [1]. Despite this, the ability of
IgA – both systemic and mucosal – to modulate the risks
of HIV infection remains relatively understudied.* Correspondence: rruprecht@txbiomed.org
1Department of Virology & Immunology, Texas Biomedical Research Institute,
7620 NW Loop 410, San Antonio, TX 78227, USA
2Southwest National Primate Research Center, 7620 NW Loop 410, San
Antonio, TX 78227, USA
© 2014 Zhou and Ruprecht; licensee BioMed
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.Review
Structure and subclasses and of IgA
The structure of IgA is similar to that of other immu-
noglobulins. Monomeric IgA consists of two heavy chains
and two light chains, which are stabilized by non-
covalent interactions. Each heavy chain is composed
of four subdomains: the variable region of the heavy
chain (VH), and the constant regions α1 (Cα1), Cα2
and Cα3, whereas the light chains have two subdo-
mains, the variable region of the light chain (VL) and
the constant region (CL) (Figure 1).
Human IgA has two closely related subclasses, termed
IgA1 and IgA2; the major difference between these two
lies in the hinge region (Table 1). In IgA1 molecules, the
hinge region contains 19 amino acids (aa) [2] and a num-
ber of O-linked oligosaccharides [3,4], whereas the hinge
region of IgA2 molecules is only 6 aa long [2] and lacks
glycosylation [5]. As a consequence of their open hinge
region, IgA1 molecules have a T-like shape, in which the
distance between Fab fragments measures approximatelyCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Human IgA1 and IgA2 molecules as monomers, dimers (dIgA1 and dIgA2, respectively) and as secretory forms (SIgA1 and
SIgA2, respectively). Green, heavy chain; yellow, light chain; red, J chain; blue, secretory component (SC); orange, O-linked oligosaccharides in
the IgA1 hinge region. N-linked oligosaccharides are shown at the approximate locations in both IgA1 and IgA2 molecules.
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between Fab regions is only 10 nm due to the shorter and
stiffer hinge region [7-9]. The structural differences
between IgA1 and IgA2 molecules are likely associated with
differential biological activities.
In human serum, approximately 90% of IgA consists
of IgA1 and 10% of IgA2 [8]. In contrast, the ratio of
IgA1 and IgA2 varies in different mucosal fluids, with
IgA1 percentages in male genital secretions and nasal
fluids reaching 80-90% and 60% in saliva [18]. Female
genital secretions and rectal fluids contain approximately
60% IgA2. Human colostrum was reported to have even
higher ratios of IgA2 compared to IgA1; the concentrationsof both components decreased during the time of lactation
to significantly lower levels in mature milk [19].
IgA in serum is mainly monomeric with dimeric or
polymeric forms ranging from <1% to 20% [2]. Polymeric
forms of serum IgA include trimers and tetramers.
In mucosal fluids, the major IgA form is secretory IgA
(SIgA). It is generated from dimeric (dIgA) secreted locally
from mature mucosal plasma cells; dIgA consists of two
IgA monomers linked covalently via their Fc portions to
the joining (J) chain. The secretory component (SC) is
added during the passage of dIgA across the epithelial
layer (see below). The open hinge region in SIgA1 makes
this molecule more susceptible than SIgA2 to proteolytic
Table 1 IgA Cα gene in different mammalian species
Species (number
of Cα genes)
Cα Gene Hinge length
region (aa)
References
Human (2) Cα1 19 [2,10]
Cα2 6
Gorilla (2) Cα1 19 [2,10-12]
Cα2 6
Chimpanzee (2) Cα1 19
Cα2 6
Orangutan (1) Cα 17
Gibbon (2) Cα1 9
Cα2 6
Rhesus macaque (1) Cα 7 [2,10-12]
Baboon (1) Cα 7













Mouse (1) Cα 12
Pig (1) Cα 9
Bovine (1) Cα 9
Dog (1) Cα 11
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such as Haemophilus influenzae and Neisseria meningiti-
dis [20-22]. It is currently not known whether SIgA1 and
SIgA2 exhibit differential susceptibility to proteolytic
cleavage by normal microbial flora in the various mucosal
fluids.
The generation of SIgA
In contrast to serum IgA, which is derived from plasma
cells in the bone marrow, SIgA is generated locally by
plasma cells located in the lamina propria below the
epithelium; these cells secrete dIgA, including J chains.
After release, the dIgA molecules bind to the polymeric
immunoglobulin receptor (pIgR) [23,24], a transmem-
brane glycoprotein of the Ig superfamily with five extracel-
lular domains expressed on the basolateral surfaces ofmucosal epithelial cells (step 1, Figure 2). Following
binding to pIgR, the dIgA-pIgR complex is endocytosed
and transported across the epithelial cell in a vesicle
(step 2, Figure 2). The J chain is crucial for the forma-
tion of the pIgR-dIgA complex and offers a binding site
for the pIgR [25]. On the apical side, the complex is
released into the lumen, a process during which proteases
cleave off SC from the pIgR (step 3, Figure 2). The final
product, SIgA, is released into the lumen either as
dimer or higher-order multimers and likely interacts with
mucus. Such interactions differ from those of IgG, which is
also present in mucosal secretions [26]. It is also possible
that SIgA1 and SIgA2 bind differentially to mucus,
given their differences in structure and glycosylation pat-
terns. Interestingly, free pIgR can also transcytose to the
apical surface and undergo proteolytic cleavage, which
results in the release of free SC into mucosal secretions
[27-29].
IgA in different species
IgA molecules have been identified in many mamma-
lian species [30]. Most only encode a single Cα gene,
thus giving rise to single IgA subclass. The number of Cα
genes in different mammalian species is summarized in
Table 1. Humans and some of the great apes encode IgA1
as well as IgA2 [31], whereas rhesus macaques and many
other species only encode one subclass [11]. Of note, the
species most frequently used to generate and analyze anti-
body responses, mice and rabbits, encode either one [32]
or 13 Cα genes [13], respectively, thus not reflecting the
human system. Consequently, the only potential animal
model to study differential IgA subclass responses may be
chimpanzees.
Methods to isolate various forms of human IgA
When evaluating existing literature regarding human IgA
responses, technical issues need to be considered. Most
publications do not distinguish between IgA1 and IgA2,
and many also do not differentiate between monomeric,
dimeric, or polymeric forms [33-39]. Furthermore, some
studies only report on serum IgA responses, whereas
others exclusively focus on IgA in mucosal fluids. Much
needs to be learned about the dynamics and specificities
of IgA responses in the systemic circulation and their rela-
tionship to IgA responses in mucosal compartments.
Current IgA isolation methods are given in Table 2. It will
be important to reassess the distribution of IgA1 and IgA2
in different human mucosal fluids with reagents and
methods with equal sensitivity, specificity and recovery for
both IgA subclasses.
Methods are available to isolate SIgA with reagents spe-
cific for SC. The fact that the open hinge region in IgA1
makes this molecule more susceptible to proteolytic cleav-
age by proteases of pathogenic bacteria could also be
Figure 2 Formation of SIgA. Dimeric IgA (dIgA) is produced by mature plasma cells in the lamina propria; these cells also produce J chains.
Step 1, dIgA interacts with the polymeric immunoglobulin receptor (pIgR; shown in blue) on the basolateral surface of epithelial cells. Step 2:
export of dIgA across the epithelial cells is mediated by pIgR. Step 3: pIgR undergoes proteolytic cleavage at the luminal side, which results in the
generation of secretory component (SC) that is retained by dIgA molecules, giving rise to secretory IgA (SIgA).
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ate between IgA1 and IgA2 versions of the various forms
of IgA, monoclonal antibodies (mAbs) are commercially
available that show a high degree of specificity for either
human IgA subclass.
In summary, it is important to review the IgA isolation
methods when judging existing literature on IgA. Much
analytical work remains to be carried out to determine
the roles of various human IgA forms – monomeric
versus dimeric or multimeric, systemic versus mucosal,
as well as IgA1 versus IgA2 – in modulating HIV
transmission.
Unanswered question regarding secretory IgA (SIgA)
A number of questions regarding the biology of SIgA
responses have not yet been fully addressed, especially
in humans and non-human primates. Important aspects
of SIgA biology have been studied in mouse models
(reviewed in [40]). According to this review, key questions
that remain to be addressed include i) the longevity of
mucosal plasma cells, ii) the need for T-cell involvement,
iii) the ability of B cells to undergo class switchrecombination locally in the lamina propria and iv), innate
versus adaptive IgA responses. It is especially important to
address such questions in non-human primate models.
Studies in mice lacking T-cell immunity have indi-
cated that some mucosal IgA responses against intes-
tinal commensal bacteria were retained [41], implying
their T-cell independence. Antigen sampling at special-
ized mucosal sites, the trafficking of B cells, and the
generation of SIgA at different mucosal sites has been
reviewed by Neutra and Kozlowski, especially with regards
to induction of adaptive mucosal immune responses by
vaccination [42].
IgA interactions with Fc receptors
Like IgG, IgA interacts with cell surface-expressed Fc
receptors, the best known one being the Fc receptor αRI
(FcαRI) [43], also known as CD89. FcαRI is encoded by
a single gene [44] and is expressed on monocytes/
macrophages, dendritic cells, neutrophils, eosinophils, and
Kupffer cells of the liver [45,46]. Through interactions
with FcαRI, IgA can activate (ADCC) [47] and comple-
ment [48]. In addition, the FcαRI-IgA interactions can also
Table 2 Human IgA isolation methods
Reagent for IgA isolation IgA site recognized IgA form recognized References





Fc Specific for all IgA1 and IgA2 forms [36,39]
Streptococcal IgA-binding peptide Fc Specific for all IgA1 and IgA2 forms [35,38]
mAbs
Anti-J chain mAb J chain Specific for dimeric and secretory
forms of IgA1 and IgA2
Commercially available
Anti-SC mAb SC Specific for secretory forms of IgA1 and IgA2
Specific anti-IgA1 mAb Constant region Specific for IgA1
Specific anti-IgA2 mAb Constant region Specific for IgA2
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and modulate phagocytosis. IgA can also interact through
its Fc moiety with Fcα/μR, known as CD351 [49,50],
which is expressed on mature B cells, macrophages,
Paneth cells [51] and on follicular dendritic cells [52]. The
consequences of the Fcα/μR-IgA interaction remain to be
elucidated. Of note, the standard ADCC assays using NK
cells as effector cells are not expected to be positive for
IgA-mediated ADCC since NK cells express neither CD89
nor CD351.
Protective Mechanisms of IgA in viral infections
Direct neutralization, immune exclusion and inhibition of
transcytosis
In mucosal fluids, SIgA provides the first line of defense
against invading viruses, as IgA can either directly
neutralize virions, mediate their adherence to mucin
glycoproteins, or aggregate them into large IgA-virion
complexes; interactions with mucus serve to retain virions
in the lumen, a phenomenon termed “immune exclusion”.
A recent passive immunization study [53] provided proof-
of-principle that dIgAs given directly into the rectal lumen
as neutralizing monoclonal antibodies (nmAbs) can pre-
vent SHIV acquisition (Figure 3A). Although the exogen-
ously administered dIgAs did not contain SC, they may
have associated with free SC, which is present in mucosal
secretions [27-29].
Vaccine-induced mucosal IgA responses can also block
HIV or SHIV infection after mucosal exposure (Figure 3B).
Plasma cells in the lamina propria secreting HIV-specific
dIgA play an important role in this protective mechanism;
after secretion from lamina propria plasma cells, anti-HIV
dIgA binds to pIgR followed by uptake into a transcytotic
vesicle. HIV-specific SIgA is released on the luminal side
after proteolytic cleavage of pIgR and retention of the
secretory component to yield SIgA. The data suggest that
SIgA can either directly neutralize incoming HIV or cross-
link it in large virion-SIgA complexes [54-59], resulting in
immune exclusion (Figure 3B).Intracellular neutralization
This mechanism was first described by Burns et al. [60]
using a rotavirus murine model. Rotavirus can cause
severe diarrhea in young children and animals. The au-
thors discovered that two oligomeric IgA mAbs directed
against VP6, a major inner viral capsid protein, could
prevent infection after oral challenge of mice. The
dIgA mAbs were inactive when administered directly
into the lumen of the intestinal tract. The authors
postulated that the non-neutralizing IgA mAbs encoun-
tered nascent viral proteins while being transported by
pIgR across epithelial cells, known to support rotavirus
replication. While these mAbs were non-neutralizing in
standard assays, they were able to bind to VP6 in the
endocytic vesicle during transepithelial transport and pre-
vent virus assembly [60]. This process is termed intracel-
lular neutralization.
Mucosal IgA as mediator of immune excretion
As described above, dIgA binds to pIgR through the Cα3
region in the presence of the J chain. This interaction
leaves the antigen-combining sites of the dIgA free.
Consequently, the question arises whether dIgA carrying
an antigenic cargo would still bind to pIgR and cross the
epithelial cell layer from the apical to the luminal side.
This question was addressed in vivo in a transgenic
mouse system by Robinson et al. [61]. After intragastric
immunization, the mice mounted strong mucosal antigen-
specific IgA responses. After intravenous administration
of the antigen, the latter was detected within epithelial
cells of the small intestinal crypts and also within epithe-
lial cells in more distal regions of the villi. Control mice
immunized with an irrelevant antigen showed no such
localization of the antigen. Antigen uptake by epithelial
cells occurred only from the basolateral side in the pres-
ence of IgA-antigen complexes in the lamina propria [61].
These data imply that IgA-antigen complexes follow the
same pIgR-mediated trans-epithelial movement as free
dIgA.
Figure 3 IgA-mediated protection against HIV/SHIV at mucosal surfaces. A. Passive immunization with a neutralizing monoclonal dIgA. After
topical administration of the neutralizing mAb in the mucosal lumen of macaques, dIgAs bind to SHIV and prevent virions from crossing the epithelial
barrier by forming large SHIV-dIgA complexes. Reports from the literature describe the presence of free SC in various mucosal fluids [27-29]. B and C.
Protection by locally produced IgA in HEPS individuals or induced by vaccination. B. Immune exclusion; inhibition of transcytosis. HIV/SHIV-specific dIgA
is produced by mature plasma cells in the lamina propria and interacts with pIgR (in blue) on the basolateral surface of epithelial cells; export of dIgA
across the epithelial cells is mediated by pIgR. The latter undergoes proteolytic cleavage at the luminal side, which results in the generation of SC that
is retained by dIgA molecules, releasing SIgA into the lumen. SIgA binds to SHIV and prevents viral invasion of epithelial cells by forming large SHIV-
dIgA complexes. C. Intracellular neutralization. After the dIgA-pIgR complex is formed intracellularly, HIV/SHIV particles that have invaded the epithelial
cells are bound and then excreted as virion-dIgA-pIgR complex. This returns the SIgA-virion complex into the mucosal lumen.
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complexed with dimeric or polymeric IgA could also
be excreted by a pIgR-mediated mechanism (Figure 4). To
test this notion, Wright et al. [62] used cell-culture sys-
tems consisting of either polarized epithelial cells stably
expressing pIgR on the basolateral surface or humanepithelial cell lines naturally expressing pIgR. A number of
oligomeric IgA mAbs targeting either HIV gp41 or gp120
were tested; controls included the same mAbs in an
IgG form or irrelevant anti-measles virus oligomeric IgA
and IgG. These investigators placed mAb-HIV immune
complexes into the bottom chamber in transwell plates
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culture fluid overlaying the apical side of a tight epithelial
layer. Transport of HIV particles was indeed observed and
correlated directly with the ability of the IgA mAbs to
bind to virions as well as to the pIgR. Excretion of HIV
particles on the apical side required HIV-specific oligo-
meric IgAs and occurred at IgA concentrations that were
in the range of those found in human mucosal fluids.
Confocal microscopy showed co-localization of HIV
antigens and anti-HIV oligomeric IgA within the polar-
ized epithelial cells; control cells lacking pIgR expres-
sion did not facilitate transepithelial transport of HIV.
It is currently not known whether the excretory function
of dIgA contributes to the clearance of viral pathogens
from inside the epithelial barrier and whether such a
mechanism plays a role in the early stages of HIV invasion
after mucosal exposure.
Anti-HIV IgA responses linked to protection
IgA responses in HIV-exposed, persistently seronegative
persons (HEPS)
A number of studies examined mucosal antibody responses
in HEPS, including mucosal IgAs [55,63-67]. Interestingly,
studies that have linked HIV-specific IgA responses with
resistance in sex workers and in persistently uninfected sex-
ual partners of HIV-positive individuals have used jacalin-
based methods to isolate mucosal IgAs. As mentioned pre-
viously, jacalin resins preferentially bind human IgA1 anti-
bodies. In some instances, such IgA isolated by jacalin was
also found in HEPS sera. Epitope mapping revealed that
mucosal IgAs targeted relatively conserved epitopes in the
membrane proximal external region (MPER) of HIV gp41
[68,69]. Cross-clade neutralization of such mucosal IgAs
from HEPS has been described [63]. Of note, HIV-
specific mucosal antibody responses were reported to be
absent or detectable in only a low fraction of HEPS in sev-
eral cohorts [70-73]. Consequently, a potential association
of HIV-specific IgAs with remaining HIV negative is un-
clear. The discrepancy of findings regarding mucosal IgA in
HEPS may be due to technical issues, including the
addition of protease inhibitors to mucosal fluids, the use of
jacalin-based IgA isolation methods, and assay sensitivity.
Vaccine-induced mucosal IgA responses linked to
protection of macaques against SHIV challenges
Virosomes displaying either an HIV gp41-derived peptide,
P1, or a truncated recombinant gp41 were administered to
Chinese-origin rhesus macaques (RMs) by intramuscular
(i.m.) priming followed by either i.m or intranasal (i.n.)
boosting. Only RMs vaccinated by the i.m./i.n. routes
developed systemic as well as mucosal antibody responses.
Four weeks after the last boost, the vaccinees were given a
total of 13 low-dose intravaginal challenge with the heter-
ologous tier 2 SHIVSF162P3. All macaques given emptyvirosomes became viremic and seroconverted. In contrast,
four out of the five vaccinees given i.m. priming followed
by i.n. boosting remained aviremic; a fifth animal had only
transient low-level viral RNA blips. None of these five vac-
cinees seroconverted, indicating protection from persistent
systemic infection. All of the protected RMs had developed
gp41-specific IgAs in vaginal secretions that blocked trans-
cytosis of HIV clade B and C strains in vitro. When the
mucosal secretion of the vaccine-protected RMs were de-
pleted either of IgA or IgG, the transcytosis inhibition was
retained only when mucosal IgGs were depleted but not
vice-versa, implying that vaccine-induced IgA was respon-
sible for blocking HIV transcytosis in vitro [74].
The protected RMs also had developed vaginal IgG
responses with neutralizing and/or ADCC activities. Inter-
estingly, plasma IgGs did not neutralize the challenge
virus. The authors concluded that vaccine-induced vaginal
IgA responses together with IgG responses were linked to
robust protection against vaginal SHIV challenges [74].
Inhibition of transcytosis by a primary HIV clade C strain
implied that the combined virosome immunogens display-
ing either peptide P1 or recombinant, truncated gp41
shared epitope determinants that were recognized cross-
clade. This is all the more interesting given that the primary
amino acid sequences showed no linear epitope identity. In
this context, it is noteworthy that Devito et al. [63] had de-
scribed earlier HIV-blocking IgAs specific for the HIV gp41
MPER region in HEPS, and Tudor et al. [75] had detected
P1-specific IgA responses in HEPS as well.
Prevention of mucosal R5 SHIV transmission by
neutralizing human monoclonal IgA1 and IgA2 in rhesus
macaques
Direct proof that mucosal IgAs can prevent primate
immunodeficiency virus transmission was provided by
passive immunization with different isotypes of the human
nmAb HGN194 that targets the conserved crown of the
V3 loop in the HIV envelope glycoprotein [53]. dIgA1,
dIgA2, and IgG1 versions of HGN194 were applied intrar-
ectally (i.r.) to RMs 30 minutes before i.r. clade C SHIV
challenge. A control pharmacokinetic study had demon-
strated that the nmAb concentrations in the rectal
fluids over time were similar for all three HGN194 iso-
types, an important control study given that dIgA forms
were used intrarectally. Unexpectedly, dIgA1 provided the
best protection against i.r. SHIV challenge, despite the fact
that all three nmAbs had similar neutralizing activity
in vitro. Among RMs passively immunized with dIgA1,
83% were protected compared to only 17% of those given
dIgA2 (P = 0.045). Better protection correlated signifi-
cantly with virion capture; dIgA1 reproducibly captured
twice as many virions compared to dIgA2 in vitro. Only
dIgA1 blocked transcytosis of cell-free virus across an
epithelial layer in vitro [53].
Figure 4 Excretion of HIV from chronically infected hosts. HIV-specific dIgA (shown in green) captures virions in the lamina propria, forming
immune complexes that shuttle across the epithelial cell after binding to pIgR (shown in blue). The latter undergoes proteolytic cleavage at the
apical site and releases an HIV-SIgA immune complex into the mucosal lumen.
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dIgAs and prevention of mucosal SHIV transmission but
also revealed a significant difference between the human
dIgA1 and dIgA2 versions of the same nmAb that had not
changed epitope specificity in the different backbones.
These data and the results of Bomsel et al. [74] imply that
AIDS vaccine strategies should focus on inducing mucosal
IgA responses as a first line of defense against HIV, a virus
predominately transmitted mucosally.
Can IgA in breastmilk protect infants from milk-borne HIV
transmission?
In areas of the world where infant mortality is high due
to lack of resources and access to safe, affordable for-
mula, exclusive breastfeeding for the first six months is
recommended by WHO [76]. Studies have shown that
exclusive breastfeeding is associated with a surprisingly
low postnatal HIV transmission rate [77].
To test whether IgA in breastmilk of HIV-positive
mothers was associated with protection of breastfeeding
infants, a nested case–control study was performed in
Zambia [78,79]. Total HIV Env-specific IgA levels were
measured in milk samples collected from 26 HIV-infected
mothers who transmitted the virus to their infants (trans-
mitters) and from 64 mothers whose infants remained
negative (non-transmitters). Overall, HIV Env-specific IgA
in breastmilk was not linked to protection. HIV Env-
specific IgA was detected more often in breastmilk of
transmitting mothers compared to non-transmitting
mothers. Unfortunately, the interpretation of the datawas complicated by the fact that: “most infected infants in
our study had detectable infection by 2 months of age,
making it difficult to distinguish postpartum- and
intrapartum-acquired infections” [78]; of the 26 in-
fected infants, only four fulfilled the criteria of defin-
ite milk-borne mother-to-child transmission according
to the authors. As a consequence, this study did not
have sufficient statistical power to provide definite an-
swers regarding a potentially protective role of IgA in
milk for infants born to HIV-positive mothers and ex-
clusively breastfed.
Are Anti-HIV IgA responses harmful?
IgA-dependent enhancement of HIV infection in vitro
Two separate studies reported enhancement of HIV repli-
cation in vitro by unfractionated, serum-derived poly-
clonal IgA. In the first study, laboratory-adapted HIVIIIB
was tested in U937 cells in the presence of either IgA from
seronegative individuals or from seropositive individuals
at different stages of HIV disease. Only modest increases
of virus replication by serum IgA were seen that could be
blocked by preincubating the cells with an anti-FcαR mAb
[80]. Similar, low-level enhancement of viral replication by
total serum IgA from seropositive individuals was observed
in primary monocytes with HIVBaL, a primary isolate. This
effect could be suppressed by pretreating the cells with IgA
isolated from HIV-seronegative individuals [81]. Together,
these studies implied FcαR-mediated enhancement of HIV
infection; however, the relevance of these in vitro findings
to mucosal HIV transmission is uncertain.
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protective IgG outcompeted by IgA?
The RV144 phase III trial had a modest 31.2% efficacy in
preventing HIV acquisition [82]. Follow-up studies to
determine correlates of risk of infection demonstrated that
plasma IgG targeting the variable loops 1 and 2 (V1-V2)
of HIV Env was associated with a decreased risk of
HIV acquisition. In contrast, plasma anti-HIV Env IgA
was linked to an increased risk of infection [83]. Another
factor favoring beneficial outcomes was ADCC activity
mediated by plasma IgG. More recently, Tomaras et al.
[84] reported that antibodies recognizing epitopes
within the first constant region (C1) of HIV gp120
mediated most of the ADCC activity observed. These
authors went on to show that two different anti-C1 IgA2
mAbs interfered with the IgG1-mediated ADCC activity,
therefore blocking a beneficial vaccine-induced antibody ef-
fector function. Follow-up clinical studies (RV305 and
RV306) using the same immunogens as in RV144 have
been initiated to analyze vaccine-induced, mucosal antibody
responses [84].
Conclusions
In vitro studies have identified several protective anti-HIV
mechanisms of IgA, including direct HIV neutralization,
inhibition of transcytosis, intracellular virus neutralization,
and excretion of infectious virus from the basolateral side
of the mucosal barrier. Anti-HIV IgA also has effector
mechanisms, such as ADCC and complement activation
via the alternative and lectin pathways. Together, these
various IgA actions represent defense mechanisms that
could benefit the host.
Mucosal IgA responses against different viruses protect
the host in various model systems [53,85-87]. The role of
mucosal anti-HIV IgA in humans is less clear, although
data from HEPS implied that mucosally produced IgA
may be responsible, at least partially, for preventing
systemic infection. Direct evidence for IgA-mediated pre-
vention of mucosal virus transmission was obtained by
passive immunization in SHIV-challenged macaques,
where mucosally administered monoclonal dIgA1 com-
pletely protected most animals, in contrast to the dIgA2
version with the same epitope specificity; better protection
was linked to better virion capture and prevention of
transcytosis [53]. Active immunization of RMs with viro-
somes displaying HIV gp41 likewise linked prevention of
persistent viremia to the induction of mucosal IgA
responses capable of blocking transcytosis in vitro [74].
Potentially problematic aspects of anti-HIV IgAs include
IgA-dependent enhancement of HIV infection in cultured
cell lines and primary monocytes [80,81], although this
enhancement was modest and was overcome by higher
concentrations of autologous IgG. The relevance of these
in vitro IgA characteristics to mucosal HIV transmissionis unclear currently. Recent data from the RV144 trial
have also raised concerns that plasma anti-HIV Env IgA
responses deprive the host of the benefits of IgG-mediated
ADCC directed against shared targets on Env [84]. The
RV144 analysis only involved plasma IgA since no muco-
sal samples were available [83,84].
In summary, while passive and active immunization
studies in macaques gave proof-of-concept that SHIV
acquisition can be prevented by mucosal IgA, the jury is
still out whether anti-HIV IgA responses will overall bene-
fit or harm the host. Future research will need to dissect
the role of anti-HIV IgA in the systemic circulation as well
as in different mucosal compartments and clearly define
which forms of anti-HIV IgA are involved at such sites at
the time of virus exposure. As our review of existing data
has shown, not all IgAs are created equal, and it is possible
that the various forms of IgA can differentially affect HIV
transmission or spread.
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